• 37 Hits
  • Search Condition : Filter (MeSH = Gefitinib)
Species Resource Title
Human and Animal Cells A431(RCB0202) Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
Human and Animal Cells A549(RCB0098) , LC-2/ad(RCB0440) , RERF-LC-KJ(RCB1313) MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Human and Animal Cells PC-9(RCB4455) Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.
Human and Animal Cells RERF-LC-KJ(RCB1313) , LC-1/sq(RCB0455) , RERF-LC-AI(RCB0444) , MS-1(RCB0725) PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Human and Animal Cells PC-9(RCB4455) Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis.
Human and Animal Cells PC-9(RCB4455) Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Human and Animal Cells PC-9(RCB4455) Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Human and Animal Cells II-18(RCB2093) A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Human and Animal Cells MRC-5(RCB0218) MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.
Human and Animal Cells RERF-LC-AI(RCB0444) , RERF-LC-KJ(RCB1313) , LC-2/ad(RCB0440) , A549 Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Human and Animal Cells 293T(RCB2202) , TE-1(RCB1894) , TE-11(RCB2100) , TE-14(RCB2101) , TE-15(RCB1951) ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Human and Animal Cells PC-9(RCB4455) The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Human and Animal Cells SSP-25(RCB1293) , HuH-28(RCB1943) Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Human and Animal Cells HSC-2(RCB1945) , HSC-3(RCB1975) , SAS(RCB1974) , Ca9-22(RCB1976) Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Human and Animal Cells A549 Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.
Human and Animal Cells 293T(RCB2202) Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Human and Animal Cells II-18(RCB2093) Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Human and Animal Cells 293(RCB1637) Up-Regulation of Transient Receptor Potential Melastatin 6 Channel Expression by Tumor Necrosis Factor-α in the Presence of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Human and Animal Cells LC-2/ad(RCB0440) EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Human and Animal Cells PC-9(RCB4455) Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.